Evaluating a chemogram for bladder cancer treatment personalization
Prognostic Performance of a Chemogram in Patients With Intermediate-grade Superficial Bladder Cancer and Invasive Bladder Cancer: Proof of Concept.
This study is testing a new method to see if a personalized treatment plan based on a chemogram can help people with bladder cancer get the right chemotherapy for their specific tumors.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Lille Catholic University Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Lomme) |
| Trial ID | NCT06403202 on ClinicalTrials.gov |
What this trial studies
This study aims to assess the effectiveness of a chemogram in patients with intermediate-grade superficial and infiltrating bladder cancer. The chemogram tests various chemotherapy and targeted treatment options based on individual clinical and anatomical data, allowing for a more personalized approach to treatment. Conducted in academic research laboratories, the study seeks to determine if chemograms can identify tumor sensitivity to specific anti-cancer therapies, potentially improving treatment outcomes. While the chemogram results will not alter the standard treatment regimen, they may help avoid unnecessary therapies for patients with resistant tumors.
Who should consider this trial
Good fit: Ideal candidates include adults with suspected bladder cancer who are likely to receive chemotherapy.
Not a fit: Patients with insufficient tumor volume or those who are pregnant or breastfeeding may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more effective and tailored treatments for bladder cancer patients, reducing unnecessary side effects.
How similar studies have performed: While the concept of chemograms is novel, similar personalized treatment approaches have shown promise in other cancer types.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Major patient * Patient with suspected bladder cancer likely to be treated with chemotherapy * Patient affiliated to a social security scheme Exclusion Criteria: * Insufficient tumor volume * Patient under guardianship * Pregnant or breast-feeding women * Patient opposed to participation in the study
Where this trial is running
Lomme
- Hôpital St Philibert — Lomme, France (Recruiting)
Study contacts
- Principal investigator: Jean-Louis Bonnal — Ghicl
- Study coordinator: Marie-Paule Lebitasy
- Email: lebitasy.marie-paule@ghicl.net
- Phone: 033 3 20 22 52 69
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.